## **Supplementary material**

Table 1: Domain-specific Inclusion and Exclusion Criteria (1,2)

Domain	Inclusion criteria	Exclusion criteria
Antiviral	Active COVID-19 infection with cycle	• 30 ml/min≤creatinine clearance<60ml/min
	threshold (Ct) value <30 times	Severe liver dysfunction (Child-Pugh C)
		known or suspected pregnancy will result in
		exclusion from any intervention that include
		Paxlovid or Azvudine
		Known hypersensitivity to an agent specified as
		an intervention in this domain will exclude a patient
		from receiving that agent
		Known HIV infection will exclude a patient from
		receiving Paxlovid or Azvudine
		Known hypersensitivity to Paxlovid or Azvudine
		•Receiving Salmeterol, Rifampicin, Tacrolimus,
		Sirolimus, Domperidone, Simvastatin,
		Rivaroxaban, Estazolam, Atorvastatin,
		Amiodarone, Propafenone, Carbamazepine as
		usual medications prior to this hospitalization or
		any administration of drugs mentioned above
	within 72 hours prior to assessment of eligibility wil	
		exclude a patient from receiving Paxlovid

## Immune modulation

- Active COVID-19 infection
- The level of IL-6 in serum was 100pg/ml and more (10 times more than upper limit of reference)
- C-reactive protein≥75 mg/L

- Patient has already received any dose of one or more of any form of  $\alpha$ -thymosin, Baricitinib or Tocilizumab during this hospitalization or is on long-term therapy with any of these agents prior to this hospital admission
- Known condition or treatment resulting in ongoing immune suppression including neutropenia prior to this hospitalization
- The treating clinician believes that participation in the domain would not be in the best interests of the patient
- Known hypersensitivity to an agent specified as an intervention in this domain
- Known or suspected pregnancy will result in exclusion from  $\alpha$ -thymosin, Tocilizumab and Baricitinib interventions.
- A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal will result in exclusion from receiving Tocilizumab
- A baseline platelet count <  $50x10^9/L$ , or neutrophil <  $0.5x10^9/L$  will result in exclusion from receiving Tocilizumab
- Active tuberculosis, malignant tumor, thrombus, pregnancy will result in exclusion from receiving Baricitinib

		• Patients who suffered from thymoma or who
		received organ transplantation will result in
		exclusion from receiving Baricitinib
Intravenous	Active COVID-19 infection	More than 14 days have elapsed since hospital
immunoglobulin		admission
		Patient has already received treatment with any
		non-trial prescribed antibody therapy (monoclonal
		antibody, hyperimmune immunoglobulin, or
		convalescent plasma) intended to be active against
		COVID-19 during this hospital admission
		•The treating clinician believes that participation in
		the domain would not be in the best interests of the
		patient
		Known hypersensitivity to an agent specified as
		an intervention in this domain
		Known previous history of transfusion-related
		acute lung injury
		Known objection to receiving plasma products
Antiplatelet	Pre-exiting disorders need antiplatelet	Clinical or laboratory bleeding risk or both that is
	before COVID-19 infection.	sufficient to contraindicate antiplatelet therapy
	Recommended for all patients with severe	Patient is already receiving antiplatelet therapy or
	and critical illness	non-steroidal anti-inflammatory drug (NSAID) or a
		clinical decision has been made to commence
		antiplatelet or NSAID therapy
		Patients otherwise eligible for the therapeutic
		anticoagulation domain will be excluded from the

Anticoagulation	Pre-exiting disorders need anticoagulation therapy before COVID-19 infection Patients otherwise eligible for the therapeutic antiplatelet domain will be included if they already have received Paxlovid	<ul> <li>antiplatelet domain if age is more than 75 years</li> <li>Creatinine clearance &lt;30ml/min, or receiving renal replacement therapy or ECMO</li> <li>Known hypersensitivity to an agent specified as an intervention in this domain will exclude a patient from receiving that agent</li> <li>Known or suspected pregnancy will result in exclusion from the P2Y12 inhibitor intervention</li> <li>Administration or intention to administer Paxlovid will result in exclusion from the P2Y12 inhibitor intervention that are using ticagrelor as the P2Y12 inhibitor</li> <li>Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy</li> <li>Known or suspected previous adverse reaction to low molecular weight heparin (LMWH) including heparin-induced thrombocytopenia (HIT).</li> <li>Patients with a platelet count of less than 50 × 10^9/L, hemoglobin level below 80 g/L, a bleeding history within the past 30 days, or a creatinine clearance of less than 30 ml/min will be excluded in therapeutic anticoagulation group</li> <li>Patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a platelet count of less than 50 x patients with a plate</li></ul>

		bleeding who need more than 400ml of blood
		transfusion, or a creatinine clearance of less than
		30 ml/min will be excluded in thromboprophylaxis
		group
Glucocorticoid	PaO2/FiO2 and imaging of Chest CT	•Known hypersensitivity to dexamethasone or
	deteriorated over time during hospitalization	methylprednisolone
		An indication to prescribe systemic glucocorticoid
		for a reason that is unrelated to the current
		episode, such as chronic corticosteroid use before
		admission, acute severe asthma, or suspected or
		proven <i>Pneumocystis jiroveci</i> pneumonia

## Reference

- 1. Chinese Thoracic S, Chinese Association of Chest Physicians Critical Care G. [Expert consensus on treatment of severe COVID-19 caused by Omicron variants]. Zhonghua Jie He Hu Xi Za Zhi 2023;46:101-10.
- 2. National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 10). in Chinese. 2022.

Table 2. Day 60 EQ VAS Results

	N	Mean (SD)	Median (IQR)
Antiviral domain			
No antiviral therapy	456	69.5(14.9)	70(60-80)
Paxlovid	241	64.4(16)	65(50-75)
Azvudine	157	67.3(15.4)	70(60-80)
Immune modulation domain			
No immune modulator	629	67.8(15.9)	70(60-80)
α-thymosin	116	68.6(14.8)	70(60-80)
Baricitinib	39	65.1(12.7)	65(55-75)
IL-6 receptor antagonist	38	60(14.9)	52.5(50-70)
Immunoglobulin domain			
No immunoglobulin	788	67.3(15.8)	70(60-80)
Intravenous immunoglobulin	70	65.4(14)	70(50-75)
Anticoagulation domain			
Thromboprophylaxis	528	67.4(15.1)	70(55-80)
Therapeutic anticoagulation	121	62(16.3)	60(50-70)
Antiplatelet domain			
No antiplatelet agent	234	72.5(15.1)	75(60-85)
Antiplatelet agent	228	65.3(13.8)	65(55-75)
Glucocorticoid domain			
No glucocorticoid	224	69.1(15.3)	70(60-80)
Glucocorticoid	719	66.4(15.6)	70(55-80)

SD denotes standard deviation; IQR, interquartile range

## **Table 3. Day 60 Disability Categories**

Table 3. Day to Disability Categories					
	Complete Disability n/N(%)	Severe Disability n/N (%)	Moderate Disability n/N (%)	Mild Disability n/N (%)	No Disability n/N (%)
Antiviral domain					
No antiviral therapy	1/458(0.2)	175/458 (38.2)	112/458 (24.5)	155/458 (33.8)	15/458 (3.3)
Paxlovid	3/236(1.3)	53/236 (22.5)	56/236 (23.7)	107/236 (45.3)	17/236 (7.2)
Azvudine	1/157(0.6)	39/157 (24.8)	45/157 (28.7)	66/157 (42)	6/157 (3.8)
Immune modulation domain					
No immune modulator	2/629(0.3)	201/629 (32)	144/629 (22.9)	249/629 (39.6)	33/629 (5.2)
α-thymosin	2/117(1.7)	35/117 (29.9)	38/117 (32.5)	38/117 (32.5)	4/117 (3.4)
Baricitinib	0/40(0)	9/40 (22.5)	5/40 (12.5)	25/40 (62.5)	1/40 (2.5)
IL-6 receptor antagonist	0/36(0)	5/36(13.9)	6/36 (16.7)	23/36 (63.9)	2/36 (5.6)
Immunoglobulin domain					
No immunoglobulin	3/785(0.4)	236/785 (30.1)	190/785 (24.2)	323/785 (41.1)	33/785 (4.2)
Intravenous immunoglobulin	2/71(2.8)	20/71(28.2)	16/71(22.5)	29/71(40.8)	4/71(5.6)
Anticoagulation domain					
Thromboprophylaxis	4/527(0.8)	162/527(30.7)	125/527(23.7)	209/527(39.7)	27/527(5.1)
Therapeutic anticoagulation	0/120(0)	22/120(18.3)	30/120(25)	59/120(49.2)	9/120(7.5)
Antiplatelet domain					
No antiplatelet agent	2/235(0.9)	128/235(54.5)	53/235(22.6)	46/235(19.6)	6/235(2.6)
Antiplatelet agent	0/228(0)	53/228(23.2)	61/228(26.8)	103/228(45.2)	11/228(4.8)
Glucocorticoid domain					
No glucocorticoid	0/223(0)	74/223(33.2)	57/223(25.6)	81/223(36.3)	11/223(4.9)
Glucocorticoid	5/717(0.7)	205/717(28.6)	175/717(24.4)	298/717(41.6)	34/717(4.7)

Table 4: Day 60 Disability Comparison

	N (survivors at day 60)	WHODAS score, median (IQR) [N]	Adjusted odd ratio (95% Crl)	P value
Antiviral domain				
No antiviral therapy	458	86.5(59-132)	1.00(reference)	
Paxlovid	236	109(73-147)	0.45(0.32,0.62)	<0.001
Azvudine	157	102(71-141)	0.68(0.47,0.97)	0.034
Immune modulation domain				
No immune modulator	629	98(65-144)	1.00(reference)	
α-thymosin	117	92(67-124)	1.43(0.94,2.18)	0.095
Baricitinib	40	135.5(79-156)	0.68(0.33,1.37)	0.282
IL-6 receptor antagonist	36	120(99-133)	0.75(0.25,2.30)	0.621
Immunoglobulin domain				
No immunoglobulin	785	99(65-141)	1.00(reference)	
Intravenous immunoglobulin	71	102(67-143)	1.68(1.00,2.82)	0.052
Anticoagulation domain				
Thromboprophylaxis	527	99(65-141)	1.00(reference)	
Therapeutic anticoagulation	120	114.5(81-156)	0.65(0.44,0.96)	0.03
Antiplatelet domain				
No antiplatelet agent	235	69(56-102)	1.00(reference)	
Antiplatelet agent	228	107.5(75-144.5)	0.62(0.38,1.02)	0.06
Glucocorticoid domain				
No glucocorticoid	223	96(61-129)	1.00(reference)	
Glucocorticoid	717	101(68-145)	1.16(0.84,1.60)	0.355

IQR denotes interquartile range; CrI, credible interval

Odds ratio parameters are for the analysis of WHODAS disability category. An OR<1 indicates reduced disability.

P value is computed from an ordinal mixture mode